Bank of America
Healthcare
Conference
May 17, 2006

Jeff Campbell
Executive Vice President
Chief Financial Officer
2

Safe Harbor Clause
Some of the information in this presentation may constitute
forward-looking statements that are subject to various
uncertainties. These uncertainties could cause actual results
to differ materially from those projected or implied. The risk
factors associated with those uncertainties are described in
the Company’s reports and exhibits filed with the Securities
and Exchange Commission. Financial information is
presented here in summary form. Full details are provided in
the Company’s most recent 10-Q report. All of this information
is available at www.mckesson.com. The Company assumes
no obligation to update or revise any such statements,
whether as a result of new information or otherwise.
3

McKesson Facts
FY06 REVENUES
Medical-Surgical
$3.1 B
$88 billion in revenues in FY06 Pharma
FY06 EPS $2.44 (excluding Solutions
Provider
$83.4 B
Securities Litigation charge and Technologies
$1.5 B
Discontinued Ops)
Over 27,000 employees FY06 OPERATING PROFIT
304 million shares outstanding Medical-Surgical
$70 M
$15 billion market cap Pharma
Founded 1833, headquartered Solutions
Provider
$1,211 M
Technologies
in San Francisco $143 M
144% Return to Shareholders since April 1, 2000
4

Delivering Value from the
Center of Healthcare
Solutions for
medication safety
Pharmaceutical & medical-
surgical distribution to all sites
Information solutions
for hospitals, payors,
home care, and
physicians
Inpatient automation
Specialty
Retail pharmacy pharmaceuticals
automation
Disease
Pharmacy outsourcing
management
Pharmaceutical
and consulting
repackaging
5

Market Leading Positions
in Healthcare Services
McKesson McKesson McKesson
Pharmaceutical Medical-
Medical-Surgical Provider Technologies
#1 in U.S., Canada, and #1 in primary care 63% of health systems
Mexico
51% of hospitals with
#1 in extended care
Large Rx repackaging 200+ beds
Private label
Leading generics provider Leader in clinical,
product offerings revenue cycle,
Specialty distribution &
and resource
Rapid growth in
patient services for
management solutions
physician office
manufacturers
pharmaceuticals More “Best in KLAS”
#1 in medical management and equipment products than any
software and services for other vendor
payors
#1 in robotic hospital
#1 in disease management pharmacy dispensing
for Medicaid agencies
#1 in bedside scanning
6

Leader in Growing Areas
Canadian Pharmaceutical
$12 B US
5-7% projected growth (1)
U.S. Medical-Surgical
$80 B
U.S. Pharmaceutical
6-8% projected growth (2)
$234 B
5-8% projected growth (1)
HIT – Hospital, Alternate Site
and Automation
$28 B
6-7% projected growth (3)
Payor – Outsourced and
Software
$8 B
(1) IMS
20-25% projected growth (4)
(2) Medical Devices & Supplies M arket Update
(3) Datamonitor, 2005
(4) Includes medical management s oftware/c ontent, diseas e management, coding, compliance ser vices
Well positioned in all growing healthcare areas
7

Long-term Relationships
with Market Leaders
Vanderbilt University Medical Center
8

McKesson’s Strategy
To bring together clinical knowledge, process
expertise, technology, and the resources of
a Fortune 16 company to fundamentally
change the cost and quality of healthcare.
Create long-term Introduce
relationships based Sell McKesson’s innovations that
on custom solutions comprehensive address emerging
that deliver offering healthcare
ROI & quality challenges
9

Six Years of Strong Growth
$ Billions
Warehouse Sales
Direct Revenues s) $88.1
sale
ota l
R (t $80.1
CAG
6%
1 $69.2
$57.1
$50.0
$42.0
$36.7
0 1 2 3 4 5 6
Y0 Y0 Y0 Y0 Y0 Y0 Y0
F F F F F F F
10

Diluted EPS
(continuing operations)*
A GR
C
25 %
$2.44
$2.18 $2.18
$1.89
$1.43
$0.65
($0.15)
00
01
02
03
04
05
06
FY
FY
FY
FY
FY
FY
FY
11
Note: EPS from continuing operations, excluding securities litigation charges.

Diluted EPS Reconciliation
($ and shares in millions, except EPS)
FY04 FY05 FY06
Net income (loss), continuing ops
$ 643 $ (160) $ 737
- as reported
Exclude:
- 1,200 45
Securities Litigation charges, net
- (390) (15)
Estimated income tax benefit
- 810 30
Net income, continuing ops, excluding
$ 643 $ 650 $ 767
Securities Litigation charges
Diluted earnings per common
share, continuing ops, excluding Securities
$ 2.18 $ 2.18 $ 2.44
(1) (2)
Litigation charges
Shares on which diluted
earnings per common
299 301 316
(2)
share were based
(1) Certain computations m ay r eflect rounding adjustments.
(2) For the year s ended Mar ch 31, 2006, 2005 and 2004, inter est exp ense, net of r elat ed incom e taxes, of $1 m illion, $6 million and $6 million has been add ed to net incom e,
excluding the Secur ities Litigation charges, for purposes of calculating diluted earning s per sh are. This calculation also includ es the impact of dilutive secur ities (stock options,
convertible junior subordinat ed debentures and restricted stock).
13

Diluted EPS Reconciliation
($ and shares in millions, except EPS)
Q4 Full Year
FY05 FY06 FY05 FY06
Net income, (loss) continuing ops
- as reported $ 258 $ 220 $ (160) $ 737
Exclude:
Securities Litigation charges (credits), net - (8) 1,200 45
Estimated income tax benefit - 3 (390) (15)
- (5) 810 30
Net income, continuing ops,
$ 258 $ 215 $ 650 $ 767
excluding Securities Litigation charges
Diluted earnings per common
share, continuing ops,
(1) (2)
$ 0.85 $ 0.68 $ 2.18 $ 2.44
excluding Secuities Litigation charges
Shares on which diluted
earnings per common
share were based (2) 305 314 301 316
(1) Certain computations m ay r eflect rounding adjustments.
(2) For the year s ended Mar ch 31, 2006, 2005 and 2004, inter est exp ense, net of r elat ed incom e taxes, of $1 m illion, $6 million and $6 million has been add ed to net incom e,
excluding the Secur ities Litigation charges, for purposes of calculating diluted earning s per sh are. This calculation also includ es the impact of dilutive secur ities (stock options,
convertible junior subordinat ed debentures and restricted stock).
14